Max Nisen, Columnist

The FDA May Be Opening an Alzheimer's Can of Worms

An accelerated approval pathway could create false hope for millions.

February 15, 2018 at 6:57 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Dr. Scott Gottlieb, commissioner of the Food and Drug Administration (FDA), testifies during a House Energy and Commerce Committee hearing concerning federal efforts to combat the opioid crisis, October 25, 2017 in Washington, DC.
Photographer: Drew Angerer

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

This was shaping up to be a bad week for Alzheimer's research, until the Food and Drug Administration intervened.

Merck & Co. Inc. on Tuesday announced it was discontinuing a prominent Alzheimer's drug trial. Biogen Inc. followed up on Wednesday with a worrying modification of a late-stage trial in the disease.